This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies

Mauricio Tohen, MD, DrPH, MBA; Michael Case, MS; Madhukar H. Trivedi, MD; Michael E. Thase, MD; Scott J. Burke, MS; and Todd M. Durell, MD

Published: February 23, 2010

Article Abstract

Objective: To characterize response profiles
of olanzapine/fluoxetine combination therapy in
treatment-resistant depression (TRD) and to investigate predictive relationships of early improvement with
olanzapine/fluoxetine combination for subsequent
response/remission during the acute phase of treatment.

Method: Results were pooled from 5 outpatient studies comparing oral olanzapine/fluoxetine combination, fluoxetine, or olanzapine for a maximum of 8 weeks in patients with TRD who had at least 1 historical antidepressant treatment failure during the current episode and who failed a prospective antidepressant therapy during the study lead-in period. Mean
Montgomery-Asberg Depression Rating Scale (MADRS) total and core mood items scores from the 8-week evaluation period were compared across treatment groups. Positive and negative predictive values (PPVs, NPVs) were computed from olanzapine/fluoxetine combination-treated patients demonstrating response and remission based on whether they demonstrated early improvement.

Results: Mean olanzapine/fluoxetine combination MADRS score reductions were significantly greater than fluoxetine by week 0.5 and olanzapine by week 1. Significantly more olanzapine/fluoxetine combination patients demonstrated MADRS onset of response compared with fluoxetine and olanzapine patients (P‘ ‰<‘ ‰.001 for both MADRS total and core mood items). In
olanzapine/fluoxetine combination patients, 38.1% exhibited MADRS total score response versus 26.9% of fluoxetine patients (P‘ ‰<‘ ‰.001) and 22.2% of olanzapine patients (P‘ ‰<‘ ‰.001). NPVs for MADRS total and core mood items response and remission ranged from 85.7% to 92.1%; PPVs ranged from 29.9% to 45.1%.

Conclusions: Olanzapine/fluoxetine combination is superior to fluoxetine and olanzapine in producing early improvement in patients with TRD. The absence of early improvement is highly predictive for overall response failure.

Trial Registration: Identifier: NCT00035321

J Clin Psychiatry

Submitted: December 23, 2008; accepted October 19, 2009.

Online ahead of print: February 23, 2010.

Corresponding author: Mauricio Tohen, MD, DrPH, MBA, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 (

Volume: 71

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF